From visits to recurring care

The unhappy arithmetic of one-off telehealth visits is that a brand pays to acquire a patient once and gets paid once. In the paid channels most brands live in, a single consult rarely covers what it cost to book it. Telehealth patient retention therefore decides whether the brand is a business at all. The clinics that compound are the ones that turn a first visit into a program, with a clinical cadence, billing that follows it, and follow-through that does not depend on a human remembering.

This post covers the four parts of that conversion: designing the subscription around the care plan, treating the rebill as a clinical event, running dunning (the process of recovering failed card payments) as patient communication, and watching the handful of numbers that predict where the book will be in six months. For the published discontinuation data on the largest vertical, see the post on GLP-1 patient retention data.

Why a single visit rarely pays back

A consult is a transaction. A program is a relationship with a billing schedule. The difference shows up in the lifetime value line: a patient who stays six months on a $199 program is worth six times a patient who leaves after the first fill, against the same acquisition cost. The unit economics calculator makes this visible by letting an operator change retained months and watch contribution move faster than any other input.

The published data on GLP-1 programs shows how steep the curve is. A Blue Health Intelligence issue brief drawn from Blue Cross Blue Shield claims found that roughly 30% of patients starting a GLP-1 stopped within the first month, and 58% stopped before they had been on treatment long enough to reach a clinically meaningful benefit. A JAMA Network Open analysis of claims data, available through PubMed Central, found that 64.8% of patients without diabetes had discontinued within a year. Those are claims populations, not telehealth cohorts, and they say nothing about any particular brand. What they show is that the default path for a patient is to leave, and that most of the leaving happens early.

Build the subscription around the care plan

The most common subscription mistake is copying software pricing: a monthly fee for access, billed on the signup anniversary. Patients are paying for an outcome, and outcomes have a natural clinical rhythm: a four-week fill cycle for most medications, a titration schedule (the planned dose increases over the first months of a GLP-1) for weight loss, periodic labs for hormone programs. The billing cycle belongs on that rhythm.

When the rebill lands the same week the refill ships and the check-in message arrives, the charge reads as treatment continuing. When it lands on an arbitrary calendar date with nothing else happening, it reads as a subscription to cancel. The mechanics follow from that: align the billing date to the shipment date at enrollment, move both together when a dose change shifts the schedule, and never let the card be charged for a month in which nothing shipped and nobody checked in.

Price the program, not the visit. A weight-loss program at one monthly price that includes medication, provider oversight, dose adjustments and messaging holds better than the same services itemized, because every itemized line is a separate decision to cancel. A patient who sees a message fee and a follow-up fee on top of medication is being invited to trim, and trimming ends in leaving.

The rebill is a clinical event

A telehealth rebill is not only a charge. In most programs it triggers a refill, and a refill requires a valid prescription with refills remaining, a provider who has reviewed the patient recently enough to satisfy the standard of care, and a pharmacy that can ship. If any of those is missing, the rebill either fails or, worse, succeeds and ships nothing. Operators who run billing in a generic subscription tool discover this the first time a prescription expires mid-cycle and the tool keeps charging.

The fix is to key the billing schedule to the prescription and the shipment rather than the reverse. Before each rebill, the system checks that the prescription is active and the next fill is authorized, prompts the provider for a renewal or a scheduled follow-up if it is not, and holds the charge until the fill can go out. The patient experiences a program that keeps working. The finance team sees a rebill rate that tracks clinical continuity instead of drifting away from it.

Dunning is retention work

Across subscription businesses in general, a meaningful share of churn is involuntary: cards expire, get reissued after a fraud alert, or bounce off a credit limit on the day the rebill runs. In a care program this failure mode is worse than lost revenue, because a failed payment silently becomes a lapsed prescription. The patient does not experience a billing error. The patient experiences treatment stopping, and a patient whose treatment stopped has a reason to look elsewhere.

The mechanics are unglamorous. Retry a failed card on a schedule that follows how issuers behave, not every hour. Ask for a card update before the card expires rather than after the decline. Keep the care relationship open through a defined grace window so a refill is not cut off on the first failure. Route persistent failures to a person who can call, because a phone call from the clinic reads as concern and an automated email reads as collections. Brands that treat dunning as a finance chore lose patients they never intended to lose; brands that treat it as patient communication keep them, and the recovered revenue costs almost nothing to re-acquire.

Most churn in a care program is drift: a failed card, a missed refill, an unanswered message. Retention work is mostly the business of catching drift early.

Automate the follow-through

Marketing automation gets patients to the first visit. Follow-through automation keeps them in the program: a refill confirmation before each shipment, a titration check-in on schedule, a lab reminder when bloodwork comes due, and an escalation to a provider when a patient reports a side effect or goes quiet. Each touch does double duty. It is clinically appropriate follow-through, and it is the retention mechanism, because a patient who hears from the clinic between visits has a reason to believe the subscription is doing something.

Timing matters as much as content. A check-in three days after a dose increase, when side effects peak, is clinical follow-through; the same message three weeks later is noise. That is why these workflows belong in the clinical system, keyed to prescriptions, shipments and lab orders, rather than in a marketing tool that cannot see any of them.

Text messages are the channel most patients respond to, and they carry their own rule. Under the Telephone Consumer Protection Act, marketing texts require prior express written consent, defined at 47 CFR 64.1200(f)(9), and the statute allows damages of $500 to $1,500 per message. Clinical reminders sit in a different category from marketing, but the line between "your refill ships Tuesday" and "add a lab panel this month" is one an operator should draw deliberately, with consent captured at enrollment and a clear opt-out on every message.

Cancellation rules are moving

Subscription health programs sit inside consumer-protection rules on automatic renewal, and those rules are in flux. The FTC's 2024 amendments to its Negative Option Rule, widely called click-to-cancel, were vacated by the Eighth Circuit, and on March 11, 2026 the FTC published an advance notice of proposed rulemaking seeking comment on what to do next. State automatic-renewal laws continue to apply on their own terms. The operational conclusion is the same either way: make cancellation as easy as enrollment, disclose the renewal terms plainly before the first charge, and send a reminder before any price change.

Easy cancellation is also good retention practice. A patient who can pause for a month while traveling stays; a patient who has to call during business hours to stop a charge disputes it with the card issuer, and a chargeback costs more than a pause.

Numbers that predict the business

Visit volume and signups flatter every dashboard and predict nothing. Five numbers, tracked by cohort, do:

• Rebill rate by cohort month: the share of each starting cohort still billing in months two, three and six.
• Voluntary and involuntary churn, split explicitly, because the fixes are completely different.
• Time to second fill, the earliest reliable signal that a patient has become a program.
• Lifetime value to acquisition cost by channel, computed on retained months rather than projected ones.
• Recovery rate on failed payments, the cheapest revenue a brand will ever re-acquire.

A brand that knows these five numbers by cohort can steer. A brand that knows only top-line revenue finds out about a retention problem two quarters after it started, when the cohorts that carried the number have already left.

Tessic Health runs this machinery for its clients on the Grow tier and above: the follow-through sequences, the rebill checks against prescription and shipment, failed-payment recovery, and the revenue, retention and lifetime-value analytics that watch them, under the client's brand. Because the platform charges $25 per completed consult and 0% medication markup with no revenue share, the retention a brand earns stays with the brand. The tiers are listed on the pricing page. The principle holds on any system: the product is the program, and the first visit is its front door.

Questions operators ask

What is a good subscription telehealth churn rate? Published benchmarks for telehealth subscriptions are mostly vendor claims, and this post does not repeat them. The usable reference points are the claims-data studies above, which describe when patients stop medication rather than when they stop paying a brand. A brand should measure its own cohorts and compare month two against month one, and month six against month three, rather than against a number from a sales deck.

How long should the dunning grace window be in a healthcare subscription? Long enough to cover a card reissue, which usually means a retry sequence over a week or more with a card-update request at the start, and short enough that a patient does not receive a second shipment without paying for the first. The exact window depends on the fill cycle.

Should a failed telehealth rebill stop the refill immediately? No. Hold the shipment, tell the patient plainly, and keep the prescription active while the card is fixed. Cancelling the prescription on the first decline converts a billing hiccup into a lapse in treatment and, very often, a lost patient.

Does the same approach work outside weight loss? Yes. Hormone therapy runs on lab cycles, hair growth and skincare on monthly fills, mental health on visit cadence. The rhythm differs; the rule of aligning the charge, the shipment and the check-in does not.